Vir Biotechnology Valuation

Is VIR * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VIR * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VIR *'s fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VIR *'s fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VIR *?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for VIR *. This is calculated by dividing VIR *'s market cap by their current preferred multiple.
What is VIR *'s n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

VIR * key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does VIR *'s PS Ratio compare to its peers?

The above table shows the PS ratio for VIR * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	12x
LAB B Genomma Lab Internacional. de	1.4x	9.9%	Mex$25.3b
2160 GNI Group	6.4x	24.6%	JP¥149.0b
NRIX Nurix Therapeutics	31.9x	28.1%	US$1.8b
A214450 PharmaResearch	8.2x	22.3%	₩2.3t
VIR * Vir Biotechnology	10.9x	23.7%	Mex$1.3b

Price-To-Sales vs Peers: VIR * is good value based on its Price-To-Sales Ratio (10.9x) compared to the peer average (16.5x).

Price to Earnings Ratio vs Industry

How does VIR *'s PE Ratio compare vs other companies in the Global Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: VIR * is expensive based on its Price-To-Sales Ratio (10.9x) compared to the Global Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is VIR *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VIR * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	10.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate VIR *'s Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.